Rubric Capital Management LP: KINIKSA PHARMACEUTICALS INTL (KNSA): Quarterly 13F Position History
As of Q2 2026, Rubric Capital Management LP reported 3,999,800 shares of KINIKSA PHARMACEUTICALS INTL (KNSA), worth $255.8M and representing 2.3% of its 13F equity book. Quarter-over-quarter share count change: + 249,800 (+6.7%) . The position first appeared in Q2 2024 and has been disclosed across 9 13F-HR filings in Pactolio's tracked window.
- 3,999,800Shares Held (Latest Filing)
- $255.8MReported Market Value (Latest Filing)
- 2.3%Portfolio Weight (% of 13F Equity Book)
- +249,800Quarter-over-Quarter Share Change
- +$75.2MQuarter-over-Quarter Value Change
- 4,000,000Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 9 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 3,999,800 | +249,800 | +6.7% | $255.8M | 2.3% | $64.0 |
| Q1 2026 | 3,750,000 | +421,347 | +12.7% | $180.6M | 2.2% | $48.1 |
| Q4 2025 | 3,328,653 | 671,347 | -16.8% | $137.3M | 1.6% | $41.3 |
| Q3 2025 | 4,000,000 | +90,194 | +2.3% | $155.3M | 2.1% | $38.8 |
| Q2 2025 | 3,909,806 | +526,567 | +15.6% | $108.2M | 1.7% | $27.7 |
| Q1 2025 | 3,383,239 | +764,136 | +29.2% | $75.1M | 1.3% | $22.2 |
| Q4 2024 | 2,619,103 | +200,000 | +8.3% | $51.8M | 0.9% | $19.8 |
| Q3 2024 | 2,419,103 | 0 | – | $60.5M | 1.0% | $25.0 |
| Q2 2024 | 2,419,103 | – | – | $45.2M | 1.2% | $18.7 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Rubric Capital Management LP first disclose a KNSA position in 13F-HR filings?
Rubric Capital Management LP first reported KINIKSA PHARMACEUTICALS INTL (KNSA) on its 13F-HR filing for the period ending 2024-06-30 (Q2 2024). The position has appeared on 9 reported quarters within Pactolio's tracked window.
What was Rubric Capital Management LP's most recent quarter-over-quarter share-count change in KNSA?
Between Q1 2026 and Q2 2026, Rubric Capital Management LP added 249,800 shares of KNSA (+6.7%), bringing the total reported position to 3,999,800 shares at a market value of $255.8M.
Does the implied price-per-share represent Rubric Capital Management LP's cost basis in KNSA?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.